Quick Answer
MapLight Therapeutics, Inc. reported Stockholders Equity of $458.37 million for fiscal year 2025.
MapLight Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $458.37M | +336.7% |
| 2024 | -$193.63M | -64.7% |
| 2023 | -$117.58M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$274.18M | -59.1% | -11.9% |
| June 30, 2025 | -$245.06M | -58.8% | -13.5% |
| March 31, 2025 | -$215.83M | -58.7% | -11.5% |
| December 31, 2024 | -$193.63M | -64.7% | -12.3% |
| September 30, 2024 | -$172.37M | — | -11.7% |
| June 30, 2024 | -$154.33M | — | -13.5% |
| March 31, 2024 | -$136.00M | — | -15.7% |
| December 31, 2023 | -$117.58M | — | — |
- MapLight Therapeutics, Inc. showed an increase of +336.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, MapLight Therapeutics, Inc.’s stockholders equity has grown by 489.8% (from -$117.58 million to $458.37 million).
- The most recent figure is from MapLight Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: